1. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
- Author
-
Ebina, K., Hashimoto, J., Shi, K., Kashii, M., Hirao, M., and Yoshikawa, H.
- Subjects
- *
THERAPEUTIC use of biochemical markers , *ACADEMIC medical centers , *ANALYSIS of variance , *BLOOD testing , *CHI-squared test , *CONFIDENCE intervals , *ENZYME-linked immunosorbent assay , *FISHER exact test , *LONGITUDINAL method , *MEDICAL cooperation , *MULTIVARIATE analysis , *OSTEOPOROSIS , *RESEARCH , *RESEARCH funding , *RHEUMATOID arthritis , *STATISTICS , *LOGISTIC regression analysis , *DATA analysis , *POSTMENOPAUSE , *DATA analysis software , *DESCRIPTIVE statistics , *PREDNISOLONE , *PHOTON absorptiometry , *TERIPARATIDE , *PHARMACODYNAMICS - Abstract
Summary: Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients. Introduction: The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis). Methods: The effects of TPTD were examined between RA ( n = 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis ( n = 62; age 71.3 years) with 77.4 % of prior BP. Results: Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %, P = 0.038), whereas it was 9.7 versus 7.9 % ( P = 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS ( β = 0.446, P = 0.005) and baseline ucOC for FN ( β = 0.554, P = 0.001), in which both showed significant negative correlation with baseline PSL dose. Conclusions: RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF